Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: Yahoo! Finance
Q4 2024 Total Revenue: $141.8 million, a 28.3% increase over Q4 2023. Q4 2024 Net Product Revenue: $141.8 million, a 30% increase over Q4 2023. Cash Position (End of 2024): $517.6 million with no debt. FirdApps Full Year Revenue (2024): $306 million, an 18.4% increase year over year. Agamri Full Year Revenue (2024): $46 million. FICOMPA Full Year Revenue (2024): $137.3 million. GAAP Net Income (2024): $163.9 million, or $1.38 per basic share and $1.31 per diluted share. Non-GAAP Net Income (2024): $276.3 million, or $2.33 per basic share and $2.21 per diluted share. Research and Development Expenses (2024): $12.6 million. SG&A Expenses (2024): $177.7 million. Effective Tax Rate (2024): 2025 Revenue Forecast: $545 million to $565 million. FirdApps 2025 Revenue Forecast: $355 million to $360 million. Agamri 2025 Revenue Forecast: $100 million to $110 million. FICOMPA 2025 Revenue Forecast: $90 million to $95 million. Warning! GuruFocus has detected 3 Warni
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Assessing Catalyst Pharma After 600% Surge and Rare Disease Expansion in 2025 [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift [Yahoo! Finance]Yahoo! Finance
- BioFlorida Fuels Innovation: Awards $90,000 in Annual Pitch Competition [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
CPRX
Earnings
- 11/5/25 - Beat
CPRX
Sec Filings
- 12/16/25 - Form 4
- 12/12/25 - Form 144
- 12/10/25 - Form 4
- CPRX's page on the SEC website